Lakewood-Amedex Biotherapeutics Inc. Common Stock
LABTStock
$3.43
Market Cap—
P/E—
Div yield—
Beta-3.00
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)459.85%
VGM Score100.00
Industry Peers — Pharmaceuticals(557)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LABTLakewood-Amedex Biotherapeutics Inc. Common Stock | — | — | A | $3.43 |
| LLYEli Lilly & Co. | D | B | B | $1127.69 |
| JNJJohnson & Johnson | D | C | B | $244.88 |
| ABBVABBVIE INC. | D | C | B | $243.14 |
| MRKMerck & Co., Inc. | C | C | B | $125.45 |
| NVSNovartis AG | C | C | B | $155.12 |
| AZNAstraZeneca PLC | C | B | C | $185.68 |
| NVONovo-Nordisk A/S | C | B | C | $47.64 |
| ABTAbbott Laboratories | C | C | D | $93.24 |
| PFEPfizer Inc. | B | C | D | $23.67 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $480.18 |
About
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.